Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 794, “Inotuzumab Ozogamicin in Combination With Low-Intensity Chemotherapy (Mini-Hyper-CVD) as Front-Line Therapy for Older Patients (≥ 60 years) With Acute Lymphoblastic Leukemia,” presented by Elias Jabbour, MD.
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 393, “R-CHOP With or Without Radiotherapy...
Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 229, “Caplacizumab, ...
Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 634, “Imetelstat, a Telomerase Inhibitor, T...
Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 409, “Efficacy and ...
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 6,